Compare Adaptive Biotechnologies Corp (ADPT) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while KraneShares Electric Vehicles and Future Mobility trades at $30. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| ADPT | KARS | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $38.01 |
52-Week Low | $10.24 | $22.17 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
KARS trades at $31.79, up 1.18% with a bearish technical signal as moving averages indicate selling pressure. The electric vehicle ETF faces industry headwinds including shifting consumer demand and geopolitical tensions affecting fuel prices. Recent news highlights Chinese EV expansion and regulatory uncertainties in the US market, while technical indicators show neutral oscillators but strong bearish momentum from moving averages.
The outlook remains cautious with industry pressures from Chinese competition and regulatory delays. Investment opportunities exist in global EV adoption trends, but risks include tariff policies and demand volatility. Key support sits at $31 with resistance at $32, requiring close monitoring of auto industry developments and policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
